At below $70, Amgen (AMGN) trades back where it was in July, 2003, and well below its and well below its September 2005 high of $85.
An antitrust claim that was an investor concern lost some stream in court recently. As a consequence Citi reiterated its "buy" rating on the stock with a $100 price target.
Amgen has also picked up the pace in the earnings area. Third quarter earnings were ahead of Wall St. expectations at $1.04 a share Analysts expected $.98. On the news Morgan Stanley raised its price target to $74 and commented: "We suspect short-term momentum will be to the upside, as expectations were low coming into the quarter, overall market sentiment remains positive, and estimates are increasing," according to Forbes.com.
According to Morningstar, Amgen’s cash flow was 32% of sales last year.
Not bad for a beaten down stock.
Douglas A. McIntyre can be reached at [email protected]. He does not own securities in companies that he writes about.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
